OXiGENE Adds Two New Directors to Its Board (Stock World)
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the Company has added two new members to its Board of Directors.

Advancis Pharmaceutical Reports on Meeting With FDA Reviewing Keflex PULSYS Phase III Trial Design (RedNova)
GERMANTOWN, Md., June 26 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation , a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it has concluded a Pre-Phase III meeting with the U.S.